Net Income (Loss) Per Share

9 Months Ended

Sep. 30, 2020

Net Income (Loss) Per Share Basic and diluted net income (loss) per common share is computed by dividing net income (loss) attributable to NantHealth by the weighted-average number of common shares outstanding during the respective periods, without consideration of common stock equivalents. If there is a net loss from continuing operations attributable to NantHealth, diluted net income (loss) per share is computed in the same manner as basic net income (loss) per share is computed, even if the Company reports net income as a result of discontinued operations attributable to NantHealth.

The following table sets forth reconciliations of the numerators and denominators used to compute basic and diluted net loss per share of common stock for the three and nine months ended September 30, 2020 and 2019:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
	Common Stock		Common Stock		Common Stock		Common Stock
Net income (loss) per share numerator:
Net loss from continuing operations	$	(11,026)	$	(16,380)	$	(68,221)	$	(52,175)
Net loss attributable to noncontrolling interests	(42)		—		(42)		—
Net loss from continuing operations attributable to NantHealth	(10,984)		(16,380)		(68,179)		(52,175)
Net (loss) income from discontinued operations attributable to NantHealth	(16)		3		31,955		1,162
Net loss attributable to NantHealth for basic and diluted net loss per share	$	(11,000)	$	(16,377)	$	(36,224)	$	(51,013)
Weighted-average shares for basic net income (loss) per share	110,929,357		110,619,905		110,859,611		110,261,279
Effect of dilutive securities	—		—		—		—
Weighted-average shares for dilutive net income (loss) per share	110,929,357		110,619,905		110,859,611		110,261,279

Basic and diluted net income (loss) per share attributable to NantHealth:
Continuing operations - common stock	$	(0.10)	$	(0.15)	$	(0.62)	$	(0.47)
Discontinued operations - common stock	$	—	$	—	$	0.29	$	0.01
Total net loss per share - common stock	$	(0.10)	$	(0.15)	$	(0.33)	$	(0.46)

The following number of potential common shares at the end of each period were excluded from the calculation of diluted net loss per share attributable to common stockholders because their effect would have been anti-dilutive for the periods presented:


	September 30,
	2020	2019
Unvested restricted stock	—	1
Unvested phantom units	—	121,244
Unvested restricted stock units	253,308	1,868,224
Unexercised stock options	10,150,724	710,892
Convertible notes	8,815,655	8,815,655